• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Lucio Gordan Outlines Challenges to Implementing a New OCM

Video

"I am not convinced yet that the Oncology Care First Model truly takes into account necessary elements, including high-cost drugs," said Lucio Gordan, MD, president and managing physician at Florida Cancer Specialists.

"I am not convinced yet that the Oncology Care First Model truly takes into account necessary elements, including high-cost drugs," said Lucio Gordan, MD, president and managing physician at Florida Cancer Specialists.

Transcript:

In your opinion, does the proposed Oncology Care First Model go far enough to address concerns that the OCM did not adequately reimburse practices for high-cost therapies?

The Oncology Care First model remains very difficult to understand, in my opinion. I think Community Oncology Alliance and others have sent several initial suggestions and recommendations to CMS, CMMI (Capability Maturity Model Integration), as to how to design Oncology Care First. I am not convinced yet that Oncology Care First truly takes into account the necessary elements, including high-cost drugs. I think we lack understanding as far as the details, as to how this will be operationalized. We really have embraced the Oncology Care Model. We do think that value-based care should obviously continue in cancer care in the United States. It is just taking maybe too quick of a step from moving from the current Oncology Care Model to Oncology Care First. There are a lot of things that need to be understood and the details need to be ironed out for us to truly embrace this as a solution for us.

Related Videos
Pregnant Patient | image credit: pressmaster - stock.adobe.com
Amit Singal, MD, UT Southwestern Medical Center
Rashon Lane, PhD, MA
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Binod Dhakal, MD, Medical College of Wisconsin, lead CARTITUDE-4 investigator
Dr Sophia Humphreys
Robert Zimmerman, MD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.